Literature DB >> 35937932

VirScan: High-throughput Profiling of Antiviral Antibody Epitopes.

Ellen L Shrock1,2, Christine L Shrock3, Stephen J Elledge1,2.   

Abstract

Profiling the specificities of antibodies can reveal a wealth of information about humoral immune responses and the antigens they target. Here, we present a protocol for VirScan, an application of the phage immunoprecipitation sequencing (PhIP-Seq) method for profiling the specificities of human antiviral antibodies. Accompanying this protocol is a video of the experimental procedure. VirScan and, more generally, PhIP-Seq are techniques that enable high-throughput antibody profiling by combining high-throughput DNA oligo synthesis and bacteriophage display with next-generation sequencing. In the VirScan method, human sera samples are screened against a library of peptides spanning the entire human viral proteome. Bound phage are immunoprecipitated and sequenced, identifying the viral peptides recognized by the antibodies. VirScan Is a powerful tool for uncovering individual viral exposure histories, mapping the epitope landscape of viruses of interest, and studying fundamental mechanisms of viral immunity. Graphical abstract.
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Antibody ; Bacteriophage display ; Epitope ; High-throughput screening ; Immunology ; PhIP-Seq ; Serology ; Synthetic biology ; VirScan ; Virus

Year:  2022        PMID: 35937932      PMCID: PMC9303818          DOI: 10.21769/BioProtoc.4464

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  18 in total

1.  Phage Display.

Authors:  George P. Smith; Valery A. Petrenko
Journal:  Chem Rev       Date:  1997-04-01       Impact factor: 60.622

2.  Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.

Authors:  Joshua A Hill; Elizabeth M Krantz; Kevin A Hay; Sayan Dasgupta; Terry Stevens-Ayers; Rachel A Bender Ignacio; Merav Bar; Joyce Maalouf; Sindhu Cherian; Xueyan Chen; Greg Pepper; Stanley R Riddell; David G Maloney; Michael J Boeckh; Cameron J Turtle
Journal:  Blood Adv       Date:  2019-11-26

3.  An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.

Authors:  Francesco Borriello; Valentina Poli; Ellen Shrock; Roberto Spreafico; Xin Liu; Novalia Pishesha; Claire Carpenet; Janet Chou; Marco Di Gioia; Marisa E McGrath; Carly A Dillen; Nora A Barrett; Lucrezia Lacanfora; Marcella E Franco; Laura Marongiu; Yoichiro Iwakura; Ferdinando Pucci; Michael D Kruppa; Zuchao Ma; Douglas W Lowman; Harry E Ensley; Etsuro Nanishi; Yoshine Saito; Timothy R O'Meara; Hyuk-Soo Seo; Sirano Dhe-Paganon; David J Dowling; Matthew Frieman; Stephen J Elledge; Ofer Levy; Darrell J Irvine; Hidde L Ploegh; David L Williams; Ivan Zanoni
Journal:  Cell       Date:  2022-02-10       Impact factor: 41.582

4.  Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.

Authors:  Kjetil Bjornevik; Marianna Cortese; Kassandra L Munger; Alberto Ascherio; Brian C Healy; Jens Kuhle; Michael J Mina; Yumei Leng; Stephen J Elledge; David W Niebuhr; Ann I Scher
Journal:  Science       Date:  2022-01-13       Impact factor: 63.714

5.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Authors:  Ben Langmead; Cole Trapnell; Mihai Pop; Steven L Salzberg
Journal:  Genome Biol       Date:  2009-03-04       Impact factor: 13.583

6.  The repertoire of maternal anti-viral antibodies in human newborns.

Authors:  Christian Pou; Dieudonné Nkulikiyimfura; Ewa Henckel; Axel Olin; Tadepally Lakshmikanth; Jaromir Mikes; Jun Wang; Yang Chen; Anna Karin Bernhardsson; Anna Gustafsson; Kajsa Bohlin; Petter Brodin
Journal:  Nat Med       Date:  2019-03-18       Impact factor: 53.440

7.  PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes.

Authors:  Divya Mohan; Daniel L Wansley; Brandon M Sie; Uri Laserson; H Benjamin Larman; Muhammad S Noon; Alan N Baer
Journal:  Nat Protoc       Date:  2018-09       Impact factor: 13.491

8.  Scalable gene synthesis by selective amplification of DNA pools from high-fidelity microchips.

Authors:  Sriram Kosuri; Nikolai Eroshenko; Emily M Leproust; Michael Super; Jeffrey Way; Jin Billy Li; George M Church
Journal:  Nat Biotechnol       Date:  2010-11-28       Impact factor: 54.908

9.  Pan-viral serology implicates enteroviruses in acute flaccid myelitis.

Authors:  Isobel A Hawes; Prashanth S Ramachandran; Akshaya Ramesh; Ryan D Schubert; Emily D Crawford; John E Pak; Wesley Wu; Carly K Cheung; Brian D O'Donovan; Cristina M Tato; Amy Lyden; Michelle Tan; Rene Sit; Gavin A Sowa; Hannah A Sample; Kelsey C Zorn; Debarko Banerji; Lillian M Khan; Riley Bove; Stephen L Hauser; Amy A Gelfand; Bethany L Johnson-Kerner; Kendall Nash; Kalpathy S Krishnamoorthy; Tanuja Chitnis; Joy Z Ding; Hugh J McMillan; Charles Y Chiu; Benjamin Briggs; Carol A Glaser; Cynthia Yen; Victoria Chu; Debra A Wadford; Samuel R Dominguez; Terry Fei Fan Ng; Rachel L Marine; Adriana S Lopez; W Allan Nix; Ariane Soldatos; Mark P Gorman; Leslie Benson; Kevin Messacar; Jennifer L Konopka-Anstadt; M Steven Oberste; Joseph L DeRisi; Michael R Wilson
Journal:  Nat Med       Date:  2019-10-21       Impact factor: 53.440

10.  Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.

Authors:  Ellen Shrock; Eric Fujimura; Tomasz Kula; Richard T Timms; I-Hsiu Lee; Yumei Leng; Matthew L Robinson; Brandon M Sie; Mamie Z Li; Yuezhou Chen; Jennifer Logue; Adam Zuiani; Denise McCulloch; Felipe J N Lelis; Stephanie Henson; Daniel R Monaco; Meghan Travers; Shaghayegh Habibi; William A Clarke; Patrizio Caturegli; Oliver Laeyendecker; Alicja Piechocka-Trocha; Jonathan Z Li; Ashok Khatri; Helen Y Chu; Alexandra-Chloé Villani; Kyle Kays; Marcia B Goldberg; Nir Hacohen; Michael R Filbin; Xu G Yu; Bruce D Walker; Duane R Wesemann; H Benjamin Larman; James A Lederer; Stephen J Elledge
Journal:  Science       Date:  2020-09-29       Impact factor: 63.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.